Faircourt Gold Income Corp
Change company Symbol lookup
Select an option...
FRCGF Faircourt Gold Income Corp
BAC-O Bank of America Corp
AFT Apollo Senior Floating Rate Fund
LVO LiveOne Inc
FSRXW FinServ Acquisition II Equity Warrant Exp 17 Feb 2026 *W EXP 02/17/2026
KVSC Khosla Ventures Acquisition III Co
FRPH FRP Holdings Inc
TSLA Tesla Inc
DOMO Domo Inc
PGP PIMCO Global StocksPLUS and Income Fund

Based in Canada
Company profile

Faircourt Gold Income Corp. (the Fund) is a Canada-based company, which provides a lower volatility investment solution for Canadian investors in the precious metals sector. The Company invests in gold equities which include senior and intermediate gold producers. Faircourt Asset Management Inc. (the Manager) is the Investment Advisor for the Company and is responsible for managing the affairs and providing portfolio management services to the Company. The Company has been created to provide investors with exposure to the global companies primarily involved in gold exploration, mining or production, while also providing a tax efficient yield in the form of monthly distributions. The Company’s investment objectives are to provide Shareholders with monthly distributions, initially targeted to yield 5% per annum, and the opportunity for capital appreciation.

Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

Merck stock dives after Citi downgrades on 'high probability' that HIV treatment will be abandoned

3:08 pm ET November 29, 2021 (MarketWatch)

By Tomi Kilgore

Drug maker's stock is the biggest loser in the Dow and the S&P 500's health care sector

Shares of Merck & Co. Inc. sank Monday, to buck the gains in the health care sector and the broader stock market, after Citi Research backed away from its bullish stance on the drug maker, citing concerns over its HIV and COVID-19 treatments.

The stock (MRK) fell 5.7% in afternoon trading toward a two-month low. The stock is the biggest decliner among the components of the Dow Jones Industrial Average , which ran up 305 points, or 0.9%, and of the SPDR S&P Health Care Select Sector exchange-traded fund (XLV), which rallied 0.6%.

The stock has now tumbled 17.6% since closing at a record $90.54 on Nov. 4.

Citi's Andrew Baum cut his rating to neutral, after being at buy for at least the past 2 1/2 years. He cut this stock price target to $85 from $105.

Baum said his "long-standing" bullish thesis on Merck was based on the "under-appreciation" of the company's drug pipeline, especially its HIV treatment islatravir, which he expected would offset the coming loss of exclusivity of its blockbuster cancer treatment Ketruda. However, he no longer expects any revenue from islatravir.

"We place a high probability that [Merck] will abandon islatravir development in the next three months given likely high regulatory concerns," Baum wrote in a note to clients.

Baum said he removed all estimates for islatravir from his financial models, following the company's announcement earlier this month that a dose-dependent decrease in lymphocyte counts was observed in a Phase 2 trial. He said that suggests its very likely that materially higher doses required would lead to "diverse and unacceptable" adverse events.

On Nov. 18, Merck said it stopped dosing in the trial, and on Nov. 23, the company announced a "temporary pause" in enrollment in the Phase 2 study.

Merck's stock has shed 9.8% since Nov. 18.

"We expect the diminishing outlook for islatravir to further expedite Merck's business development efforts," Baum wrote. "We open a negative catalyst watch on the stock along with today's report."

But disappointment over islatravir isn't Merck's only problem.

Baum said the clinical profile of Merck's antiviral to treat COVID-19, Lagevrio, continues to deteriorate, putting estimates for Lagevrio for next year and beyond at "material risk." He said it was "obvious" to him from inception that Lagevrio would have a risk evaluation and mitigation strategy (REMS) drug safety program required by the Food and Drug Administration because of risk of birth defects.

Don't miss MarketWatch's daily "Coronavirus Update" column.

"Since that time, we have learnt that Lagevrio's efficacy is materially lower than that reported by either monoclonals such as Regeneron's Ronapreve as well as Pfizer's Paxlovid (on an interim analysis)," Baum wrote.

He also believes it is likely that resistance will emerge over time to monotherapy Lagevrio usage.

"We expect the FDA to recommend monoclonal antibodies to be preferred therapy in immunocompromised patients in order to reduce the risk of resistance," Baum wrote.

As a result, he said the FDA could end up limiting Lagevrio approval to only non-vaccinated or immunocompromised patients."

Merck's stock has lost 4.3% year to date, while shares of Regeneron Pharmaceuticals Inc. (REGN) have climbed 36.1% and of Pfizer Inc. (PFE) have hiked up 44.2%. Meanwhile, the SPDR health care ETF has advanced 17.0% this year and the Dow has gained 15.0%.

-Tomi Kilgore


(END) Dow Jones Newswires

November 29, 2021 15:08 ET (20:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.